MA-PTC
1.7.2020 22:02:08 CEST | Business Wire | Press release
For the first time in the event’s decade-long history, the annual LiveWorx® digital transformation event took place online, uniting tens of thousands of industry leaders across the world. Chaired by presenting sponsor, PTC (NASDAQ: PTC), the one-day event featured more than 120 sessions spanning topics ranging from Augmented Reality (AR) , Artificial Intelligence (AI), 5G, Robotics, Software as a Service (SaaS) , Industrial Internet of Things (IIoT) , Product Lifecycle Management (PLM) , and Computer-Aided Design (CAD) , and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005892/en/
“This year’s virtual event brought to life the magic, excitement, and drive for transformative change that we all experience at the annual in-person version,” said Jim Heppelmann, President and CEO, PTC. “I was particularly pleased to see the force of change magnified inside and outside of this year’s event. For the global society, 2020 has been a year of challenge and growth. I look forward to seeing how this year’s energy and drive will be matched in next year’s event.”
Energizing Change
In support of movements and causes that shape the world in which the technology community operates, the LiveWorx event recognized four charities as beneficiaries for donations stemming from attendee actions throughout the event. For each attendee who entered the virtual Networking Lounge, shared their experience on social media using #LiveWorx, or completed an online scavenger hunt, approximately $1 per action was donated to charities including WWF - World Wildlife Fund , International Rescue Committee , Save the Children , and Black Girls CODE . Following the event’s final keynote session, all donations were matched by presenting sponsor, PTC.
“Bringing to life the Black Girls CODE story during this year’s LiveWorx event enabled us to raise awareness of our mission across the globe, and reinforce why we need to confront this crisis today to ensure a brighter and more inclusive tomorrow,” said Kimberly Bryant, Founder and CEO, Black Girls CODE. “While there is still a lot of work to do, I am proud to have had the opportunity to share this message, and will continue to champion inclusion for all of the women entering the STEM community.”
As part of its mission to foster inclusion across the technology industry, LiveWorx continuously endeavors to reflect more gender, racial, and geographic diversity in STEM fields represented at the event. At this year’s event, 21% of presenters identified as female or non-binary, 27% of presenters were Black, Indigenous, and People of Color (BIPOC), and 23% of presenters resided outside the United States.
Thriving in the ‘New Normal’
Over the course of the one-day event, attendees heard from technology experts across the community, including the following keynote headliners:
- Jim Heppelmann, President and CEO of PTC , who spoke about how the accelerating pace of digital transformation has forced many companies to "disrupt, or be disrupted", but the recent crisis has taught organizations a new set of principles about the role of technology in an era of disruption.
- Kimberly Bryant, Founder and CEO of Black Girls CODE , who shared the Black Girls CODE story, from its founding to its current transformational moment, as well as contemporary and historical case studies of resilience and leadership by women and people of color in times of crisis.
- Eduarda Camacho, Executive Vice President and Chief Customer Officer of PTC and Kevin Wrenn, Executive Vice President of Products at PTC , who focused on how companies should be prioritizing the use of best-in-class technology that will meet their changing needs during times of disruption and accelerated digital transformation.
To replay LiveWorx keynotes, track spotlights, and more, access the LiveWorx 2020 Content Archive . Event replays will be available through Spring 2021.
Major Product Announcements Put Industrial Enterprise Technology at Precipice of Future
Coinciding with the momentum and excitement surrounding LiveWorx 20, PTC shared key product releases from its ThingWorx® IIoT Platform , and Windchill® PLM Software offerings; recent advancements following November’s acquisition of the Onshape® SaaS technology ; and the launch of the new Factory Insights as a Service product in collaboration with sponsors Rockwell Automation and Microsoft.
Alongside this year’s Title Sponsor, Analog Devices, 11 companies supported LiveWorx 20 including Pinnacle Sponsors Ansys, AT&T Business, Ericsson, EY, and Transition Technologies; and Premier Sponsors Archer Grey, Deloitte, EPLAN, Hewlett Packard Enterprise, and Kalypso.
About PTC (NASDAQ: PTC)
PTC enables global manufacturers to realize double-digit impact with software solutions that enable them to accelerate product and service innovation, improve operational efficiency, and increase workforce productivity. In combination with an extensive partner network, PTC provides customers flexibility in how its technology can be deployed to drive digital transformation – on premises, in the cloud, or via its pure SaaS platform. At PTC, we don’t just imagine a better world, we enable it.
PTC, LiveWorx, ThingWorx, Windchill, Onshape, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005892/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
